Final results of brentuximab vedotin combined with ifosfamide-carboplatin-etoposide in first refractory/relapsed Hodgkin lymphoma: a lymphoma study association phase I/II study. - Université de Lille Accéder directement au contenu
Article Dans Une Revue Leukemia & lymphoma Année : 2022

Final results of brentuximab vedotin combined with ifosfamide-carboplatin-etoposide in first refractory/relapsed Hodgkin lymphoma: a lymphoma study association phase I/II study.

A. Stamatoullas
  • Fonction : Auteur
H. Ghesquières
  • Fonction : Auteur
P. Feugier
  • Fonction : Auteur
M. André
  • Fonction : Auteur
F. Le Bras
  • Fonction : Auteur
A. C. Gac
  • Fonction : Auteur
C. Borel
  • Fonction : Auteur
T. Gastinne
  • Fonction : Auteur
P. Quittet
  • Fonction : Auteur
V. Ribrag
  • Fonction : Auteur
S. Guidez
  • Fonction : Auteur
E. Nicolas-Virelizier
  • Fonction : Auteur
A. Berriolo-Riedinger
  • Fonction : Auteur
T. Vander Borght
  • Fonction : Auteur
V. Edeline
  • Fonction : Auteur
P. Brice
  • Fonction : Auteur

Résumé

This phase I/II study assessed the combination of brentuximab vedotin (BV) with ifosfamide-carboplatin-etoposide (ICE) as a second-line therapy in refractory/relapsed (R/R) classical Hodgkin lymphoma (cHL) patients. Phase I study was designed to determine the maximum tolerated dose (MTD) of BV (10 patients) and phase II evaluated the rate of complete metabolic response (CMR) after 2 cycles of BV-ICE (42 patients). There were no dose-limiting toxicities (DLT) during phase I recommending BV 1.8 mg/kg for phase II. Twenty-six patients (61.9%) achieved CMR after 2 cycles of BV-ICE and 37 patients (88%) were transplanted. With a median follow-up of 38 months, the 3-year progression free survival (PFS) and overall survival (OS) rate were 64.3% and 100%, respectively. Hematological toxicities (81%) and infections (21%) were the most frequent adverse event encountered BV-ICE regimen is feasible with manageable toxicities and could be an alternative to other salvage treatments.
Fichier non déposé

Dates et versions

hal-04151676 , version 1 (05-07-2023)

Identifiants

Citer

A. Stamatoullas, H. Ghesquières, P. Feugier, M. André, F. Le Bras, et al.. Final results of brentuximab vedotin combined with ifosfamide-carboplatin-etoposide in first refractory/relapsed Hodgkin lymphoma: a lymphoma study association phase I/II study.. Leukemia & lymphoma, 2022, Leukemia & lymphoma, 63 (13), pp.3063-3071. ⟨10.1080/10428194.2022.2107204⟩. ⟨hal-04151676⟩

Collections

UNIV-LILLE
4 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More